Public Disclosure of Transfers of Value (ToV) to Healthcare Professionals (HCPs) & Healthcare Organisations (HCOs)

*/ Background From January 2015, pharmaceutical companies in the United Kingdom (UK), Ireland and across Europe have been capturing and recording details of payments made to Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) with whom we work, for individual public disclosure from June 2016, also known as Transfer of Value (ToV).The requirement is part of an industry wide move towards greater trust and transparency between pharmaceutical companies, the people we work with and the public. This requirement is included in the Association of the British Pharmaceutical Industry (ABPI) Code of Practice.ToV includes, for example, the payments we make to HCPs for speaking at and chairing meetings; registration fees; participation at advisory board meetings; and remuneration and/ or travel and accommodation costs for attendance at educational meetings.Janssen fully supports the public disclosure of ToV payments made by pharmaceutical companies to HCPs or HCOs. As an ethical company we feel it is important to be transparent and open about all of our interactions and we sincerely hope you agree.

The Janssen approach to Continuous Professional Development (CPD) programmes

*/ Sponsoring and supporting CPD programmes is part of our responsibility for the medicines we develop.  

For Healthcare Professionals


Content Date of Preparation: March 2017
Item Code: PHGB/JMC/0317/0001